Comparison of 1 Month vs. 12 Months DAPT in Patients Undergoing PCI With Genoss® DES (GENOSS-DAPT)
Coronary Artery Disease
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring Percutaneous Coronary Intervention, Dual Antiplatelet Therapy, Drug Eluting Stent
Eligibility Criteria
Inclusion Criteria: Subjects must be at least 19 years of age Subjects undergoing elective PCI with Genoss® Drug Eluting Stents Subject who can understand the risk, benefit and treatment alternatives, and when he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure Exclusion Criteria: Subjects presenting with acute myocardial infarction Subjects with less than 1 year of life expectancy Subjects presenting with cardiogenic shock Subjects requiring anticoagulation (warfarin, direct oral anticoagulant), or those requiring antiplatelet agents other than aspirin and P2Y12 inhibitors. Subjects with history of intracranial hemorrhage (ICH) Known hypersensitivity or contraindications to study medications (aspirin, clopidogrel), or drugs used in the procedure (heparin, contrast media, sirolimus). Those with contrast hypersensitivity can be enrolled if symptom/signs can be controlled by anti-histamines or steroids.
Sites / Locations
- Seoul St. Mary's HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
1 Month DAPT
12 Months DAPT
Patients will receive 300 mg of aspirin and 300 mg of clopidogrel before PCI unless previously medicated with antiplatelet agents. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for 1 month following PCI. Following 1 month, clopidogrel 75 mg once daily will be given for 11 months.
Patients will receive 300 mg of aspirin and 300 mg of clopidogrel before PCI unless previously medicated with antiplatelet agents. Aspirin 100 mg plus clopidogrel 75 mg once daily will be given for 12 months following PCI.